Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Government representatives, dementia associations and WHO experts gathered in London to share progress, tackle challenges and strengthen collaboration on developing and implementing effective National Dementia Plans worldwide.
On 15 April, at the ADI Conference in Lyon, France, ADI shared the Alzheimer’s Disease Atlas, a first-of-its-kind website mapping the global landscape of Alzheimer’s disease.
DY Suharya, ADI’s Asia Pacific Regional Director participated in the Walk the Talk for Dementia from Sarria to Santiago de Compostela in Spain.
On 13 August, Argentina’s Health and Budget Committees approved the Dementia Bill, marking a major step towards the country’s first National Dementia Plan. Congressman and neuroscientist Facundo Manes urged the government to allocate funding for the law, which now moves to the full Chamber of Deputies before reaching the Senate. ADI welcomes this development as Argentina advances towards making dementia a national health priority.
1 September marks the beginning of World Alzheimer’s Month. This year, we are raising awareness and encouraging our global network and beyond to ask more questions about dementia.
As part of ADI's ongoing regional commitment to dementia policy, Diego Aguilar, Regional Director for the Americas, completed a high-impact country visit to Mexico that combined academic engagement, civil society coordination, and high-level government and industry dialogue.
This month, ADI’s Regional Director for the Asia Pacific, DY Suharya, partook in a number of important meetings and events both in Lyon, France at the WHO Academy, and in Hanoi, Vietnam, alongside Vietnam International Organisation for Better Ageing (VIOBA), who are currently partaking in ADI’s Membership Development Programme.
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
This announcement reaffirms the Scottish Medicines Consortium’s decision of 10 February 2025, meaning that no disease-modifying therapies for Alzheimer’s disease are currently approved for use in Scotland.
In June, ADI’s Regional Director for the Americas, Diego Aguilar, attended a national meeting of Alzheimer’s associations in San Juan, Argentina. The meeting sought to unite lawmakers, civil society, healthcare professionals and more from across Argentina in an effort to call for legislation surrounding Alzheimer’s under the banner of #LeyAlzheimerYa (#AlzheimersLawNow).